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Background: The purpose of this paper is to report on the bacterial species isolated from patients 
with bacterial conjunctivitis participating in three clinical trials of besifloxacin ophthalmic 
suspension, 0.6%, and their in vitro antibacterial susceptibility profiles.
Methods: Microbial data from three clinical studies, conducted at multiple clinical sites in 
the US and Asia were integrated. Species were identified at a central laboratory, and minimum 
inhibitory concentrations were determined for various antibiotics, including β-lactams, fluoro-
quinolones, and macrolides.
Results: A total of 1324 bacterial pathogens representing more than 70 species were isolated. 
The most common species were Haemophilus influenzae (26.0%), Streptococcus pneumoniae 
(22.8%), Staphylococcus aureus (14.4%), and Staphylococcus epidermidis (8.4%). H. influenzae 
was most frequently isolated among patients aged 1–18 years, while S. aureus was most preva-
lent among those .65 years. Drug resistance was prevalent: Of H. influenzae isolates, 25.3% 
were β-lactamase positive and 27.2% of S. pneumoniae isolates were penicillin-intermediate/
resistant; of S. aureus isolates, 13.7% were methicillin-resistant (MRSA), and of these, 65.4% 
were ciprofloxacin-resistant, while 45.9% of S. epidermidis isolates were methicillin-resistant 
(MRSE), and, of these, 47.1% were ciprofloxacin-resistant. Besifloxacin was more potent than 
comparator fluoroquinolones overall, and particularly against Gram-positive bacteria. Against 
ciprofloxacin-resistant MRSA and MRSE, besifloxacin was four-fold to $ 128-fold more potent 
than other fluoroquinolones.
Conclusions: While the pathogen distribution in bacterial conjunctivitis has not changed, drug 
resistance is increasing. Patient age and local antibiotic resistance trends should be considered 
in the treatment of this ocular infection. Besifloxacin showed broad-spectrum in vitro activity 
and was particularly potent against multidrug-resistant staphylococcal isolates.
Keywords: besifloxacin, fluoroquinolones, in vitro activity, ocular isolates, bacterial 
conjunctivitis
Introduction
Conjunctivitis is an inflammation of the thin, transparent mucous membrane covering 
the eye.1 Bacterial conjunctivitis is a common external ocular infection that affects 
persons of all ages.2,3 Although acute conjunctivitis can be viral in nature, the majority 
of cases in children and approximately 50% of cases in adults are caused by bacteria.2,4 
Some of the more common causative organisms can be components of the normal eye-
lid flora (eg, Staphylococcus aureus, Staphylococcus epidermidis) or nasopharyngeal 
flora (eg, Haemophilus influenzae, Streptococcus pneumoniae).1,2,5–7 Other common Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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pathogens that can cause bacterial conjunctivitis include 
Moraxella spp, Neisseria spp, Corynebacterium spp, and 
other Streptococcus spp.2
Besifloxacin, an N-1 cyclopropyl, 8-chloro-fluoroqui-
nolone, was developed for the topical treatment of ocular 
infections. Besifloxacin demonstrates potent inhibition of 
both bacterial DNA gyrase and topoisomerase IV noted for 
some fluoroquinolones. Cambeau et al found besifloxacin 
to be as active against the DNA gyrase of S. pneumoniae as 
against topoisomerase IV .8 In vitro studies showed the new 
fluoroquinolone to be effective against both Gram-positive 
and Gram-negative bacteria, as well as multidrug-resistant 
strains9 and to be rapidly bactericidal for the common patho-
gens of bacterial conjunctivitis.10,11
Besifloxacin ophthalmic suspension 0.6% was approved 
in 2009 by the US Food and Drug Administration for the 
treatment of bacterial conjunctivitis. Three clinical trials were 
conducted to evaluate the clinical and microbiological efficacy 
of besifloxacin ophthalmic suspension 0.6% compared with 
vehicle, or moxifloxacin ophthalmic solution 0.5% dosed three 
times daily for 5 days.12–14 Integrated clinical microbiological 
eradication rates for the three studies are described in the com-
panion paper by Morris et al.15 Here we describe those bacterial 
pathogens most commonly isolated from patients in these stud-
ies and their in vitro antibacterial susceptibility to besifloxacin, 
comparator fluoroquinolones, and other   ophthalmic antibacte-
rial drugs. Pathogen distribution was further characterized by 
the age of the patient and by geography.
Methods
studies
Microbiological data for bacterial isolates from three pro-
spective, randomized, multicenter, double-masked clinical 
trials (two vehicle-controlled and one active-controlled) 
evaluating the clinical safety and efficacy of besifloxacin 
ophthalmic suspension 0.6% in the treatment of bacterial 
conjunctivitis were integrated. A general description of the 
trial designs is presented in the companion manuscript by 
Morris et al.15 Individual study results have been reported 
previously.12–14
In each study, microbiological cultures of the conjunc-
tival cul-de-sac were taken at visit 1 (day 1), visit 2 (day 
4 ± 1 or day 5 ± 1),12–14 and visit 3 (day 8 or 9) prior to 
administration of the morning treatment dose. Microbiologi-
cal samples were collected on a sterile swab and inserted 
into validated transport medium. The collection procedure 
was repeated with a second swab for viral culture using 
viral transport medium. All swabs were transported under 
refrigerated or frozen conditions to a central laboratory 
(Covance Central Laboratory Services, Indianapolis, IN) 
for analysis. Briefly, 0.5 mL and 0.1 mL aliquots of the 
suspended specimen were inoculated onto chocolate agar 
and trypticase soy agar with 5% sheep blood. Two serial 
10-fold dilutions were also inoculated onto separate plates 
of each medium for quantitative plate counts. All inoculated 
plates were incubated at 35°C in 5%–7% CO2 atmosphere, 
and bacterial colonies were counted after 24 and 48 hours 
of incubation. A specimen sample (0.1 mL) and two 10-fold 
dilutions for yeast culture were inoculated onto Sabouraud 
dextrose agar and incubated at 30°C. Yeast/mycelial colonies 
were counted after a total of 48–120 hours (2–5 days) of 
incubation. For viral culture, a 0.2 mL aliquot of specimen 
suspended in transport medium was inoculated into appro-
priate cell lines, incubated for 1 hour at 36°C, then washed, 
refed with maintenance media, and observed daily for 2–3 
weeks for cytopathic effect. Commercial immunofluorescent 
reagents were used to identify adenovirus and herpes sim-
plex virus.
Bacterial isolates were considered causative of the con-
junctivitis if the colony count equaled or exceeded the thresh-
old value on the Cagle list as modified by Leibowitz.16,17
in vitro susceptibility testing
In vitro susceptibilities to antibacterial agents were determined 
for all bacterial isolates at or above the Cagle threshold 
at baseline.16,17 Antibacterial agents evaluated included 
besifloxacin, moxifloxacin, azithromycin, ciprofloxacin, 
gatifloxacin, levofloxacin, and ofloxacin. Penicillin antimicrobial 
susceptibilities were determined for S. pneumoniae and beta-
hemolytic streptococci, and oxacillin susceptibilities were 
determined for all Staphylococcus species. Susceptibility 
testing was conducted on microtiter plates manufactured by 
Covance Central Laboratory. Minimum inhibitory concentra-
tions (MICs) were determined by broth microdilution according 
to the procedure recommended by the Clinical and Laboratory 
Standards Institute (CLSI).18,19 Isolates from selected species 
were further characterized by their antimicrobial resistance 
phenotype. Ciprofloxacin was chosen to determine sensitivity 
or resistance to fluoroquinolones. H. influenzae isolates were 
classified as β-lactamase positive or negative. Strains of S. 
aureus and S. epidermidis were designated methicillin-sensitive 
or methicillin-resistant based on current CLSI breakpoints for 
oxacillin.20,21 Similarly, S. pneumoniae isolates were desig-
nated as being penicillin-sensitive, penicillin-intermediate, 
or penicillin-resistant based on CLSI breakpoints for oral 
penicillin.20,21 As an exclusively topical agent, besifloxacin Clinical Ophthalmology 2011:5
Table 1 Bacterial pathogens in order of decreasing prevalence
Organism n (%) Organism n (%) Organism n (%)
Haemophilus influenzae 344 (26.0) Stenotrophomonas maltophilia 9 (0.7) Streptococcus pyogenes 5 (0.4)
Streptococcus pneumoniae 302 (22.8) Streptococcus salivarius 9 (0.7) nonfermentative gram-negative rod 4 (0.3)
Staphylococcus aureus 190 (14.4) Brevibacterium spp 8 (0.6) Rothia mucilaginosa 4 (0.3)
Staphylococcus epidermidis 111 (8.4) Corynebacterium pseudodiphtheriticum 8 (0.6) Staphylococcus caprae 4 (0.3)
Streptococcus mitis groupa 45 (3.4) Corynebacterium striatum 8 (0.6) Streptococcus sanguinis 4 (0.3)
CDC coryneform group g 29 (2.2) Pseudomonas aeruginosa 8 (0.6) Achromobacter xylosoxidans 3 (0.2)
Streptococcus mitis 20 (1.5) Staphylococcus lugdunensis 8 (0.6) Acinetobacter calcoaceticus 3 (0.2)
Streptococcus oralis 18 (1.4) Corynebacterium macginleyi 6 (0.5) Corynebacterium spp 3 (0.2)
Streptococcus sppa 13 (1.0) Corynebacterium propinquum 6 (0.5) Granulicatella adiacens 3 (0.2)
Moraxella catarrhalis 12 (0.9) Proteus mirabilis 6 (0.5) Neisseria meningitidis 3 (0.2)
Aerococcus viridans 10 (0.8) Staphylococcus warneri 6 (0.5) Staphylococcus haemolyticus 3 (0.2)
Moraxella lacunata 9 (0.7) Enterococcus faecalis 5 (0.4) Streptococcus anginosus 3 (0.2)
Serratia marcescens 9 (0.7) Haemophilus parainfluenzae 5 (0.4) Viridans streptococci 3 (0.2)
Staphylococcus hominis 9 (0.7) Staphylococcus capitis 5 (0.4)
Notes: aIsolates that were identified to the species level were listed separately. Species and phenotypes with less than three isolates: Abiotrophia defectiva (n = 1); Acinetobacter 
johnsonii (1); Acinetobacter spp (1); Bacillus spp (1); Brevibacterium casei (1); Brevundimonas vesicularis (1); CDC coryneform group i1 (1); Citrobacter koseri (1); Coagulase-negative 
staphylococci (2); Corynebacterium afermentans (2); Corynebacterium amycolatum (1); Corynebacterium argentoratense (2); Corynebacterium auris (1); Corynebacterium jeikeium 
(2); Corynebacterium minutissimum (2); Corynebacterium urealyticum (2); Eikenella corrodens (1); Enterobacter cloacae (1); Enterobacter sakazakii (1); fermentative gram-negative 
rod (1); Gemella morbillorum (2); Gemella spp (2); Kingella denitrificans (1); Klebsiella oxytoca (2); Klebsiella ozaenae (1); Kocuria kristinae (2); Leminorella spp (1); Micrococcus 
spp (2); Moraxella catarrhalis, β-lactamase negative (1); Moraxella nonliquefaciens (1); Moraxella spp (1); Morganella morganii (2); Neisseria gonorrhoeae (2); Neisseria sicca (1); 
Neisseria subflava (1); Pasteurella multocida (1); Pseudomonas fluorescens (1); Staphylococcus chromogenes (1); Staphylococcus intermedius (1); Staphylococcus xylosus (2); Streptococcus 
agalactiae (1); Streptococcus anginosus group (1); Streptococcus dysgalactiae (2); Streptococcus milleri group (1); Streptococcus parasanguinis (2); and Streptococcus thermophilus (1).
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susceptibility test interpretive criteria (ie, breakpoints) have 
not been established; however, quality control ranges for 
besifloxacin susceptibility testing were included.22 Initial 
fluoroquinolone MIC testing spanned a drug concentration 
range of 0.004–8 µg/mL. All besifloxacin MICs were within 
the initial test drug concentration range (#8 µg/mL). Because 
initial MIC testing of several S. aureus and S. epidermidis iso-
lates resulted in at least one fluoroquinolone comparator MIC 
exceeding the highest concentration (8 µg/mL) tested, these 
isolates were retested in triplicate with a higher range of drug 
concentrations for all fluoroquinolones (up to 512 µg/mL) to 
obtain endpoint values for all fluoroquinolones.
integrated analyses
Microbiological data from all three studies were pooled for a 
comprehensive, integrated analysis. The proportions of indi-
vidual species at or above threshold across the three studies 
were tabulated along with their in vitro susceptibilities and 
antimicrobial resistance phenotypes. While only one eye per 
patient (study eye) was considered for the primary efficacy 
endpoints of clinical resolution and bacterial eradication in the 
clinical study analyses,12–14 both eyes could contribute microbio-
logical samples to the integrated analyses if both eyes had signs 
and symptoms of bacterial conjunctivitis and the pathogenic 
organism in the nonstudy eye was different from the organism 
in the study eye. In addition, more than one species from each 
eye was included if each species met the Cagle criteria.
Results
Pathogen distribution
A total of 1324 bacterial pathogens were isolated at baseline 
(visit 1) at or above the Cagle threshold from 1041 culture-
confirmed bacterial conjunctivitis patients across the three 
clinical studies, with 92.8% (1229/1324) and 7.2% (95/1324) 
of the bacterial isolates obtained from patients at US and Asian 
clinical sites, respectively. Although some isolates could only 
be identified to the genus or group level, more than 70 different 
species of bacteria were identified. Isolates identified included 
430 streptococci, 349 Haemophilus spp, 342 staphylococci, 
73 corynebacteria, 24 Enterobacteriaceae, 23 Moraxella spp, 
9 Pseudomonas spp, and 7 Neisseria spp. In addition, 148 
patients were positive for viral cultures at baseline. Of the 
viral positive cultures, 94.6% (140/148) were identified as 
adenovirus and 5.4% (8/148) were identified as herpes simplex 
virus; 28 of these viral pathogens were isolated from eyes that 
also yielded bacterial isolates at or above threshold, indicating 
that 2.7% (28/1041) of bacterial culture-positive eyes were 
coinfected with virus. Yeast was rarely recovered from subjects 
with bacterial conjunctivitis. The few fungal isolates recovered 
included Candida parapsilosis (n = 1) at baseline and Penicil-
lium spp (n = 1), Candida glabrata (n = 1), and Saccharomyces 
cerevisiae (n = 1) at subsequent visits.
Table 1 presents a listing of bacterial species isolated 
across the three clinical studies in decreasing order of 
prevalence. Gram-positive and Gram-negative bacteria Clinical Ophthalmology 2011:5
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Figure  1  Distribution  of  Haemophilus  influenzae,  Streptococcus  pneumoniae, 
Staphylococcus aureus, Staphylococcus epidermidis, and other species among bacterial 
conjunctivitis isolates stratified by age group.
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contributed 66.9% (886/1324) and 33.1% (438/1324) of the 
isolates, respectively, and the four most prevalent species, 
H. influenzae, S. pneumoniae, S. aureus, and S. epidermidis, 
together accounted for 71.5% (947/1324) of all isolates. The 
species distribution among isolates obtained from patients 
enrolled at Asian clinical sites was similar to that observed 
for patients enrolled at US sites (data not shown), with the 
exception of S. pneumoniae, which accounted for 3.2% (3/95) 
of isolates from Asian clinical sites, compared with 24.3% 
(299/1229) of isolates from US clinical sites.
Of the isolates, 11.8% (156/1324) were contributed by 
patients aged 1–2 years, 32.3% (428/1324) by patients aged 
3–18 years, 40.7% (539/1324) by patients aged 19–64 years, 
and 15.2% (201/1324) by patients aged 65 years and older. 
Figure 1 presents the pathogen distribution by age group. 
H. influenzae was the most prevalent species in patients aged 
1–2 years, representing 46.8% (73/156) of the isolates in that 
age group, and gradually decreased in prevalence as the patient 
age increased. However, even in the patients aged 65 years 
and older, 13.4% (27/201) of all isolates were H. influenzae. 
S. pneumoniae was commonly isolated from patients 1–64 
years of age and peaked with 29.7% (127/428) in the 3–18-year 
age group. Only 9.5% (19/201) of isolates in the 65+ age group 
were S. pneumoniae. Other species of Streptococcus, most 
notably those belonging to the Streptococcus mitis group, were 
also more prevalent in younger than in older patients (data not 
shown). Moraxella spp accounted for only 23 isolates, but those 
were more frequently isolated from patients aged 1–2 years 
and 3–18 years compared with older patients.
In the older patient population, staphylococci and 
corynebacteria were most prevalent. S. aureus contributed 
10.3% (16/156) of isolates to the youngest age group and 
increased in prevalence with the age of the population to 
22.4% (45/201) of all isolates from patients 65 years and 
older. Similarly, unspeciated staphylococci and S. epidermidis 
increased from 0% to 1.9% (0/156 and 3/156, respectively) in 
1–2-year-old patients to 8.5% to 11.0% (17/201 and 22/201) 
in the oldest patient group. The same trend was noted for 
corynebacteria, which increased in frequency with age from 
1.3% (2/156) to 13.4% (27/201). The number of Enterobac-
teriaceae also increased with patient age, ranging from 0.3% 
(2/584) for patients 18 years or younger, to 2.6% (14/539) 
to 4.0% (8/201) for patients aged 19–64 years and 65 years 
and older, respectively. Age-specific isolation patterns were 
also observed for Moraxella spp, but the number of isolates 
was too small to draw any conclusions.
Overall in vitro susceptibility
Table 2 presents the MIC values for besifloxacin and com-
parator antibacterial agents for those species with $10 iso-
lates recovered for all Gram-positive and all Gram-negative 
bacteria and for bacteria overall. For all 1324 isolates, the 
MIC50 and MIC90 for besifloxacin were 0.06 and 0.25 µg/mL, 
respectively. These values were lower than those of the other 
fluoroquinolones, where the comparable MIC50 values were 
in the range of 0.125–0.5 µg/mL, and the MIC90 values were 
in the range of 0.5–2 µg/mL. MIC50 and MIC90 values for 
Gram-positive bacteria were widely spread, showing a 16-fold 
difference between the most and least potent fluoroquinolone. 
Besifloxacin was the most potent agent in this group, followed 
by moxifloxacin, gatifloxacin, levofloxacin, ciprofloxacin, and 
ofloxacin. Against Gram-negative bacteria, values for the five 
fluoroquinolones varied only by a two-fold dilution for the 
MIC50 and a four-fold dilution for the MIC90. Against these 
organisms, the older fluoroquinolones, ciprofloxacin and levo-
floxacin, remained the most potent antibacterial agents.
Figure 2 shows the MIC distributions for besifloxacin and 
ciprofloxacin for Gram-positive and Gram-negative isolates 
obtained from patients at US clinical sites. The 825 Gram-
positive isolates among US isolates had MIC50/MIC90 values 
of 0.06/0.25 µg/mL for besifloxacin and 0.5/2 µg/mL for 
ciprofloxacin. Many Gram-positive isolates had ciprofloxa-
cin MICs $ 4 µg/mL, reflecting the ciprofloxacin resistance 
among staphylococcal isolates (discussed further below). 
The corresponding MIC50/MIC90 values for the 404 Gram-
negative isolates were 0.03/0.25 µg/mL for besifloxacin and 
0.015/0.06 µg/mL for ciprofloxacin.
Figure 3 presents the MIC distributions for besifloxacin 
and ciprofloxacin for all isolates obtained from patients 
at Asian clinical sites, which included sites in India and 
the Philippines. While the MIC distributions for isolates Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Table 2 In vitro activity of besifloxacin and comparator anti-infectives against bacterial pathogens from three clinical trialsa
Organism Minimum inhibitory concentration (μg/mL)
BES CIP GAT LVX MXF OFX AZM
All isolates (n = 1324) range 0.008–8 #0.004–.8 #0.004–.8 #0.004–.8 #0.004–.8 0.008–.8 0.008–.8
MiC50 0.06 0.25 0.125 0.25 0.125 0.5 2
MiC90 0.25 2 0.5 1 0.5 2 .8
gram-positive (n = 886) range 0.008–8 0.015–.8 0.008–.8 0.008–.8 0.008–.8 0.008–.8 0.008–.8
MiC50 0.06 0.5 0.25 0.5 0.125 1 1
MiC90 0.25 4 1 2 0.5 4 .8
gram-negative (n = 438) range 0.008–8 #0.004–.8 #0.004–8 #0.004–8 #0.004–8 0.015–.8 0.015–.8
MiC50 0.03 0.015 0.015 0.03 0.03 0.03 2
MiC90 0.5 0.125 0.25 0.125 0.25 0.25 .8
Aerococcus viridans (n = 10) range 0.015–0.03 0.06–0.125 0.06–0.5 0.125–0.25 0.03–0.06 0.125–0.25 4–.8
MiC50 0.03 0.06 0.25 0.125 0.03 0.25 4
MiC90 0.03 0.06 0.5 0.25 0.06 0.25 8
CDC coryneform  
group g (n = 29)
range 0.008–2 0.03–8 0.03–8 0.06–.8 0.03–.8 0.125–.8 0.06–.8
MiC50 0.015 0.06 0.06 0.06 0.03 0.125 0.125
MiC90 0.125 0.5 0.5 1 0.25 2 .8
Haemophilus influenzae 
  All (n = 344)
  BL-neg (n = 253)
  BL-pos (n = 87)
range 0.008–0.5 #0.004–1 #0.004–0.5 #0.004–1 0.008–1 0.015–2 0.015–.8
MiC50 0.03 0.015 0.015 0.03 0.03 0.03 2
MiC90 0.06 0.015 0.03 0.03 0.06 0.06 4
range 0.008–0.5 0.008–1 0.008–0.5 0.008–1 0.008–1 0.015–2 0.015–.8
MiC50 0.03 0.015 0.015 0.03 0.03 0.03 2
MiC90 0.06 0.015 0.03 0.03 0.06 0.06 4
range 0.008–0.06 #0.004–0.06 #0.004–0.06 #0.004–0.06 0.008–0.125 0.015–0.125 0.125–4
MiC50 0.03 0.015 0.015 0.03 0.03 0.03 2
MiC90 0.06 0.015 0.03 0.03 0.06 0.06 2
Moraxella catarrhalis
  All (n = 12)
  BL-pos (n = 11)
range 0.06–0.25 0.03–1 0.03–0.5 0.06–2 0.06–0.5 0.06–4 0.03–0.25
MiC50 0.06 0.03 0.06 0.06 0.125 0.125 0.06
MiC90 0.25 0.5 0.25 1 0.5 2 0.25
range 0.06–0.25 0.03–1 0.03–0.5 0.06–2 0.06–0.5 0.06–4 0.06–0.25
MiC50 0.06 0.03 0.06 0.06 0.125 0.125 0.06
MiC90 0.25 0.5 0.25 1 0.5 2 0.25
Staphylococcus aureus
  All (n = 190)
  MssA-Cs (n = 144)
  MrsA-Cs (n = 9)
  MssA-Cr (n = 17)
  MrsA-Cr (n = 17)
range 0.008–8 0.06–.8 0.03–.8 0.03–.8 0.03–.8 0.125–.8 0.06–.8
MiC50 0.03 0.5 0.125 0.25 0.06 0.5 2
MiC90 0.5 .8 4 8 2 .8 .8
range 0.008–1 0.06–1 0.03–.8 0.03–0.5 0.03–0.25 0.125–1 0.06–.8
MiC50 0.03 0.5 0.125 0.25 0.06 0.5 2
MiC90 0.06 0.5 0.25 0.25 0.125 0.5 .8
range 0.03–0.06 0.25–0.5 0.06–0.25 0.25–0.5 0.06–0.06 0.25–1 2–.8
MiC50 0.06 0.5 0.125 0.25 0.06 0.5 .8
range 0.125–2 4–.8 0.25–.8 1–.8 0.25–.8 2–.8 2–.8
MiC50 0.5 .8 4 8 2 .8 .8
MiC90 2 .8 .8 .8 8 .8 .8
range 0.125–8 4–.8 0.25–.8 1–.8 0.5–.8 2–.8 2–.8
MiC50 0.5 .8 4 8 4 .8 .8
MiC90 4 .8 .8 .8 .8 .8 .8
Staphylococcus epidermidis  
  All (n = 111)
  Msse-Cs (n = 50)
range 0.03–4 0.125–.8 0.06–.8 0.125–.8 0.06–.8 0.25–.8 0.5–.8
MiC50 0.06 0.25 0.125 0.25 0.125 0.5 1
MiC90 0.5 .8 2 8 4 .8 .8
range 0.03–0.25 0.125–1 0.125–0.5 0.125–0.5 0.06–0.25 0.25–1 0.5–.8
MiC50 0.06 0.25 0.125 0.25 0.125 0.5 1
MiC90 0.06 0.25 0.25 0.25 0.125 0.5 .8
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Table 2 (Continued)
Organism Minimum inhibitory concentration (μg/mL)
BES CIP GAT LVX MXF OFX AZM
  Mrse-Cs (n = 27) range 0.03–0.06 0.125–0.5 0.06–0.5 0.125–0.25 0.06–0.25 0.25–0.5 0.5–.8
MiC50 0.06 0.25 0.125 0.25 0.125 0.5 .8
MiC90 0.06 0.25 0.25 0.25 0.125 0.5 .8
    Msse-Cr (n = 10) range 0.5–2 8–.8 2–.8 4–.8 1–.8 4–.8 0.5–.8
MiC50 0.5 .8 2 8 4 .8 1
MiC90 1 .8 8 .8 8 .8 .8
    Mrse-Cr (n = 24) range 0.25–4 4–.8 1–.8 1–.8 1–.8 8–.8 1–.8
MiC50 0.5 8 2 8 2 8 .8
MiC90 4 .8 .8 .8 .8 .8 .8
Streptococcus mitis (n = 20) range 0.06–0.25 0.25–4 0.25–1 0.5–2 0.06–0.5 1–4 0.06–8
MiC50 0.125 1 0.5 1 0.125 2 2
MiC90 0.125 2 1 1 0.25 2 4
S. mitis group (n = 45) range 0.03–1 0.06–.8 0.06–2 0.125–.8 0.03–2 0.25–.8 0.03–.8
MiC50 0.125 1 0.5 1 0.125 2 2
MiC90 0.25 4 0.5 2 0.25 4 8
Streptococcus oralis (n = 18) range 0.015–0.25 0.03–4 0.03–1 0.125–2 0.015–0.5 0.125–4 0.06–.8
MiC50 0.125 2 0.5 1 0.25 2 4
MiC90 0.25 4 1 2 0.25 4 .8
Streptococcus pneumoniae
  All (n = 302)
  PssP (n = 220)
  PisP (n = 71)
  PrsP (n = 11)
range 0.03–0.25 0.125–.8 0.125–1 0.125–2 0.06–1 0.5–4 0.06–.8
MiC50 0.06 0.5 0.25 0.5 0.125 1 0.125
MiC90 0.125 1 0.5 1 0.125 2 .8
range 0.03–0.25 0.125–2 0.125–1 0.125–2 0.06–1 0.5–4 0.06–.8
MiC50 0.06 0.5 0.25 0.5 0.125 1 0.125
MiC90 0.125 1 0.5 1 0.125 2 0.25
range 0.03–0.125 0.25–2 0.125–0.5 0.5–2 0.06–0.5 1–2 0.06–.8
MiC50 0.06 0.5 0.25 0.5 0.125 1 8
MiC90 0.06 0.5 0.5 1 0.125 2 .8
range 0.03–0.125 0.25–.8 0.25–1 0.5–1 0.125–0.25 1–2 0.06–.8
MiC50 0.06 1 0.5 1 0.125 2 8
MiC90 0.125 1 0.5 1 0.125 2 .8
Unspeciated streptococci  
(n = 13)
range 0.015–0.25 0.03–4 0.03–1 0.125–2 0.015–0.5 0.125–4 0.125–.8
MiC50 0.03 0.06 0.5 0.125 0.06 0.25 8
MiC90 0.125 1 1 1 0.5 2 .8
Note: aspecies isolated from $10 patients.
Abbreviations: BES, besifloxacin; CIP, ciprofloxacin; GAT, gatifloxacin; LVX, levofloxacin; MXF, moxifloxacin; OFX, ofloxacin; AZM, azithromycin; OXA, oxacillin; PEN, 
penicillin; BL-neg, β-lactamase negative; BL-pos, β-lactamase positive; MSSA-CS, methicillin-susceptible ciprofloxacin-susceptible S. aureus; MrsA-Cs, methicillin-resistant 
ciprofloxacin-susceptible S. aureus; MSSA-CR, methicillin-susceptible ciprofloxacin-resistant S. aureus; MRSA-CR, methicillin-resistant ciprofloxacin-resistant S. aureus; Msse-
CS, methicillin-susceptible ciprofloxacin-susceptible S. epidermidis; MRSE-CS, methicillin-resistant ciprofloxacin-susceptible S. epidermidis; Msse-Cr, methicillin-susceptible 
ciprofloxacin-resistant S. epidermidis; MRSE-CR, methicillin-resistant ciprofloxacin-resistant S. epidermidis; PssP, penicillin-susceptible S. pneumoniae; PisP, penicillin-intermediate 
S. pneumoniae; PrsP, penicillin-resistant S. pneumoniae.
obtained from US clinical sites had a distinct peak, MIC 
values for isolates obtained from Asian sites were more 
widely distributed, and ciprofloxacin MICs $4 µg/mL 
were more common, indicating that isolates from Asian 
sites were overall more resistant to ciprofloxacin compared 
with isolates from US sites. The increase in ciprofloxacin 
MIC90 values between isolates from US and Asian sites was 
noted overall for Gram-positive and Gram-negative bacteria 
and specifically for S. aureus and H. influenzae (discussed 
further below).
in vitro susceptibility of most prevalent 
genera
Of the H. influenzae isolates, 25.3% (87/344) were 
β-lactamase positive. As expected, H. influenzae MIC50/MIC90 
values were low for all fluoroquinolones tested regardless of 
β-lactamase status. Although no fluoroquinolone-resistant 
isolates were recovered, two strains with elevated MIC values 
of 1 µg/mL for ciprofloxacin, levofloxacin, and moxifloxacin 
were identified. H. influenzae isolates from Asian clinical 
sites had higher MIC90 values for fluoroquinolones than those Clinical Ophthalmology 2011:5
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Figure 2 Distribution of minimum inhibitory concentrations for besifloxacin (light 
gray)  and  ciprofloxacin  (dark  gray)  for  825  Gram-positive  (A)  and  438  gram-
negative isolates from the Us (B).
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from US sites, with MIC90 value ranges of 0.25–1 µg/mL for 
isolates from Asian sites (n = 12) and 0.015–0.06 µg/mL for 
isolates from US sites (n = 332).
Overall, besifloxacin was the most active agent tested 
against all streptococcal isolates. Among S. pneumoniae 
isolates, 72.8% (220/302) were penicillin-susceptible, 
23.5% (71/302) were penicillin-intermediate (PISP), and 
3.6% (11/302) were penicillin-resistant (PRSP). Penicillin 
susceptibility/resistance did not influence fluoroquinolone 
MIC50/MIC90 values. Among PISP and PRSP isolates, the 
azithromycin MIC50 values were 8 µg/mL, and MIC90 values 
were .8 µg/mL, indicating that dual resistance to azithromy-
cin and penicillin is not uncommon in S. pneumoniae. The 
MIC50/MIC90 values for each of the fluoroquinolones were 
similar against Streptococcus oralis, S. mitis, and S. mitis 
group isolates; besifloxacin was the most potent, followed 
by moxifloxacin, gatifloxacin, levofloxacin, ciprofloxacin, 
and ofloxacin.
Among S. aureus isolates, 75.8% (144/190) were methicillin-
susceptible and ciprofloxacin-susceptible, 8.9% (17/190) 
were methicillin-susceptible and ciprofloxacin-resistant 
(MSSA-CR), 4.7% (9/190) were methicillin-resistant and 
ciprofloxacin-susceptible, 8.9% (17/190) were resistant to 
both antibacterials (MRSA-CR), and 1.6% (3/190) were 
ciprofloxacin-intermediate (two methicillin-susceptible and 
one methicillin-resistant). Based on MIC50/MIC90 values, 
besifloxacin was the most potent fluoroquinolone against all 
of these phenotypes. Against ciprofloxacin-resistant isolates of 
S. aureus, MIC50 and MIC90 values for besifloxacin were at least 
four-fold lower than for the next most active fluoroquinolone, 
moxifloxacin. MIC90 values for azithromycin were .8 µg/mL 
for all resistance phenotypes of S. aureus. Azithromycin 
resistance was especially prominent among MRSA isolates, 
with at least 50% of all isolates having MIC values .8 µg/mL. 
S. aureus isolates from US clinical sites had different MIC 
values compared with those from Asian sites. The MIC50 
values for the fluoroquinolones for isolates from US clinical 
sites (n = 170) ranged from 0.03–0.5 µg/mL compared with 
0.5 µg/mL to more than 8 µg/mL for isolates from Asian sites 
(n = 20). In contrast, the MIC90 value for oxacillin was higher 
in isolates from US clinical sites compared with Asian sites 
(.8 µg/mL and 0.5 µg/mL, respectively). Consistent with this 
finding, 13 of the 17 MSSA-CR isolates in the overall data set 
came from patients in Asia, whereas all 26 MRSA isolates were 
obtained from clinical sites in the US, including 17 isolates 
that were also ciprofloxacin-resistant.
Among S. epidermidis isolates, 45.0% (50/111) were 
methicillin-susceptible and ciprofloxacin-susceptible, while 
24.3% (27/111) were methicillin-resistant and ciprofloxacin-
susceptible. A further 9.0% (10/111) and 21.6% (24/111) of 
isolates were methicillin-susceptible, ciprofloxacin-resistant, 
and methicillin-resistant and ciprofloxacin-resistant 
(MRSE-CR). Besifloxacin MIC50 values were the lowest for 
the ciprofloxacin-resistant isolates (0.5 µg/mL) regardless 
of methicillin susceptibility, followed by gatifloxacin and 
moxifloxacin (2–4 µg/mL) and ciprofloxacin, levofloxacin, 
and ofloxacin (8 µg/mL to more than 8 µg/mL). The MIC90 
values were $8 µg/mL for all fluoroquinolones except 
besifloxacin. Azithromycin MIC90 values were .8 µg/mL for 
all S. epidermidis isolates regardless of methicillin-resistant 
or ciprofloxacin-resistant phenotype.Clinical Ophthalmology 2011:5
Table 3 In vitro activity of besifloxacin and comparator fluoroquinolones against ciprofloxacin resistant Staphylococcus aureus and 
Staphylococcus epidermidis: results of the expanded range retest
Organism Fluoroquinolone MIC (μg/mL) MIC90 versus 
besifloxacin Range MIC50 MIC90
MssA–Cr (n = 14) Besifloxacin 0.5–2 0.5 1 –
Moxifloxacin 2–16 2 4 4×
Gatifloxacin 2–16 4 8 8×
Levofloxacin 4–128 8 16 16×
Ciprofloxacin 16–256 32 128 128×
MrsA–Cr (n = 15) Besifloxacin 0.5–16 1 4 –
Moxifloxacin 2–128 4 64 16×
Gatifloxacin 2–256 8 64 16×
Levofloxacin 4–512 16 512 128×
Ciprofloxacin 16–256 128 256 64×
Msse–Cr (n = 9)a Besifloxacin 0.5 0.5
Moxifloxacin 2–4 4
Gatifloxacin 2–4 4
Levofloxacin 8–16 16
Ciprofloxacin 8–128 64
Mrse–Cr (n = 13) Besifloxacin 0.5–8 0.5 4 –
Moxifloxacin 2–32 4 32 8×
Gatifloxacin 2–64 4 64 16×
Levofloxacin 4–256 16 256 64×
Ciprofloxacin 8–64 64 64 16×
Note: aDue to the limited isolates, only the MiC50 value is given.
Abbreviations: MSSA-CR, methicillin-susceptible ciprofloxacin-resistant Staphylococcus aureus; MRSA-CR, methicillin-resistant ciprofloxacin-resistant S. aureus; Msse-
CR, methicillin-susceptible ciprofloxacin-resistant Staphylococcus epidermidis; MRSE-CR, methicillin-resistant ciprofloxacin-resistant S. epidermidis; MiC, minimum inhibitory 
concentration.
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To assess these relative potency differences against 
ciprofloxacin-resistant staphylococcal isolates further, any 
isolates with an MIC . 8 µg/mL for any of the fluoroquino-
lones tested in the initial analysis were retested at higher drug 
concentrations. Results of the retest are shown in Table 3. 
For MSSA-CR, besifloxacin showed a 4–128-fold greater 
potency compared with the other fluoroquinolones, while 
for MRSA-CR, besifloxacin showed a 16–128-fold greater 
potency compared with other fluoroquinolones. Likewise, 
for MRSE-CR, besifloxacin showed an 8–64-fold greater 
potency compared with other fluoroquinolones.
Overall, besifloxacin was the most potent antibacterial 
agent tested against corynebacteria, while ofloxacin was 
the least potent fluoroquinolone. The MIC50/MIC90 values 
for besifloxacin against CDC coryneform group G were 
0.015 µg/mL and 0.125 µg/mL. In contrast, the comparators, 
ie, moxifloxacin, gatifloxacin, ciprofloxacin, and levofloxa-
cin, had MIC50 values that were 2–4-fold higher and MIC90 
values that were 2–8-fold higher.
in vitro susceptibility of other species of 
ophthalmic interest
Table 4 presents susceptibility data for less frequently isolated 
ocular pathogens of particular interest in ophthalmology, 
namely Neisseria spp, Pseudomonas aeruginosa, and 
Serratia marcescens. Eight P . aeruginosa isolates were 
obtained in the three clinical studies. Ciprofloxacin was the 
most active fluoroquinolone against P . aeruginosa, with MIC 
values ranging from 0.125 µg/mL to 1 µg/mL. Less active 
were besifloxacin (MIC range 1–4 µg/mL) and moxifloxacin 
(MIC range 1–8 µg/mL). The MIC values for Neisseria 
spp (n = 7) varied from 0.008 µg/mL and 0.25 µg/mL for 
  besifloxacin to #0.004 µg/mL and 2 µg/mL for ciprofloxacin. 
Nine S. marcescens isolates were obtained in the three clinical 
studies. Ciprofloxacin was the most active fluoroquinolone 
against S. marcescens, with MIC values ranging from 0.03 
to 0.5 µg/mL.
Discussion
The primary objective of this study was to report on the 
bacterial pathogen distribution across three clinical trials 
of besifloxacin ophthalmic suspension 0.6% in the treat-
ment of bacterial conjunctivitis and to report on the in vitro 
antibacterial susceptibility of these pathogens. The clinical 
antimicrobial efficacy of besifloxacin integrated across 
these three clinical trials is described in the companion 
paper by Morris et al.15 A total of 1324 bacterial patho-
gens were isolated across these studies from 1041 patients Clinical Ophthalmology 2011:5
Table 4   In  vitro  activity  of  besifloxacin  and  comparator 
fluoroquinolones against pathogens of ophthalmic interest
MIC (μg/mL)
Organism Fluoroquinolone Range MIC50
Neisseria spp  
(n = 7)a
Besifloxacin 0.008–0.25 0.015
Moxifloxacin 0.008–1 0.015
Gatifloxacin 0.008–0. 5 0.25
Levofloxacin 0.008–2 0.015
Ciprofloxacin #0.004–2 0.03
Pseudomonas aeruginosa  
(n = 8)
Besifloxacin 1–4 2
Moxifloxacin 1–8 2
Gatifloxacin 0.5–4 1
Levofloxacin 0.5–2 1
Ciprofloxacin 0.125–1 0.25
Serratia marcescens  
(n = 9)
Besifloxacin 0.125–1 0.5
Moxifloxacin 0.125–4 0.5
Gatifloxacin 0.06–1 0.25
Levofloxacin 0.06–0.5 0.25
Ciprofloxacin 0.03–0.5 0.125
Note: aincludes Neisseria meningitidis (n = 3), Neisseria gonorrhoeae (n = 2), Neisseria 
sicca (n = 1), Neisseria subflavia (n = 1).
Abbreviation: MiC, minimum inhibitory concentration.
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with culture-confirmed bacterial conjunctivitis, with H. 
influenzae, S. pneumoniae, S. aureus, and S. epidermidis 
being the most prevalent species identified. Other species of 
Corynebacterium, Streptococcus, and Staphylococcus were 
less frequently isolated, while only a few members of the 
Acinetobacter, Enterobacteriaceae, Moraxella, Neisseria, and 
Pseudomonas spp were recovered. Consistent with previous 
reports,4,5 2.7% of eyes at baseline yielding bacterial isolates 
were coinfected with virus, primarily adenovirus, indicating 
that bacterial and viral infections can occur together.
Previous studies on the etiology of bacterial conjunctivitis 
reported the same or similar bacterial pathogens, although 
sometimes with different frequencies.1,7,23,24 These differences 
might be due to several factors, including bacterial culture 
conditions, nomenclature, detection methods, patient age and 
geographic origin, as well as the threshold used to characterize 
an isolate as pathogenic. Sampling the surface of the eyes of 
healthy volunteers has shown that most conjunctivae are colo-
nized by various bacterial species, such as staphylococci and 
corynebacteria.1 Cagle based his definition of a conjunctivitis 
pathogen on the number of bacteria isolated from a patient 
relative to the number of bacteria of the same species isolated 
from healthy subjects.16 If the number of bacteria from a patient 
exceeded a predetermined species-specific threshold level, then 
the isolate was considered to be the cause of the disease. The 
Cagle criteria were applied in the current analysis.
The present study shows differences in the relative patho-
gen distribution of bacterial conjunctivitis by age. In both the 
1–2-year and 3–17-year age groups, H. influenzae was the 
most frequently isolated pathogen, followed by S. pneumoniae 
and other streptococci. In patients 18–64 years of age, the 
most common pathogens were S. pneumoniae, H. influenzae, 
and S. aureus. In patients 65 years and older, S. aureus was 
the most prevalent isolate, followed by corynebacteria and 
H. influenzae. In general, the contribution of H. influenzae, 
S. pneumoniae, other streptococci, and Moraxella catarrhalis 
to the number of bacterial conjunctivitis isolates decreased 
with increasing patient age, while staphylococci, coryne-
bacteria, and Gram-negative species (Enterobacteriaceae, 
Neisseria spp, Pseudomonas spp) increased in prevalence 
with increasing patient age. These results are consistent with 
other studies.7,23,25,26
The overall species contribution was similar between 
the US and Asian clinical sites, with the exception of 
S. pneumoniae, which was far less prevalent among isolates 
from Asian sites. Mahajan et al reported on the etiology of 
bacterial conjunctivitis in India and likewise found a low 
prevalence of S. pneumoniae isolates, specifically 7.5%.24 
Isolates obtained from clinical sites in Asia and the US 
also differed in their antibacterial resistance profiles, most 
notably for S. aureus and H. influenzae. For both species, 
MIC values for all of the fluoroquinolones were higher for 
isolates obtained from Asian clinical sites compared with US 
sites, while for S. aureus oxacillin MIC values were higher in 
isolates obtained from US sites compared with Asian sites.
Approximately one-fourth of H. influenzae and S. pneu-
moniae isolates were β-lactamase-positive and penicillin-
intermediate-resistant, respectively, a trend which has been 
reported previously.25,27 Cavuoto et al and Adebayo et al 
recently reported an increase in methicillin resistance among 
S. aureus isolates from bacterial conjunctivitis patients.23,28 
Similarly, in this study, 13.7% of S. aureus isolates and 45.9% 
of S. epidermidis isolates were methicillin-resistant, and, of 
these, a further 65.4% and 47.1% were also ciprofloxacin-
resistant. In addition, many of the methicillin-resistant and 
ciprofloxacin-resistant isolates were also resistant to azithro-
mycin, indicating that resistance to two or three antibacterial 
agents is not uncommon. This is consistent with previous 
studies of ocular MRSA isolates in which we found similar 
multidrug resistance trends among isolates characterized as 
hospital-associated as well as community-acquired.29 While 
multidrug resistance among ocular isolates has been reported 
in various surveillance studies,30–32 to our knowledge this 
finding represents the largest and most recent analysis of 
multidrug resistance observed in prospective and controlled 
clinical studies of bacterial conjunctivitis. Thus, while the 
spectrum of causative pathogens associated with bacterial Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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conjunctivitis has not changed, multidrug resistance among 
common conjunctivitis pathogens is evolving.
The in vitro potency of besifloxacin was similar to or 
exceeded that of comparator antibacterials. Against Gram-
positive isolates, besifloxacin was the most potent drug, 
followed by moxifloxacin, gatifloxacin, levofloxacin, and 
ciprofloxacin. Against Gram-negative bacteria, ciprofloxacin 
was the most potent antibacterial, while the potency of besi-
floxacin was similar to that of moxifloxacin. In agreement 
with previous reports,32–35 besifloxacin’s potency against 
ciprofloxacin-resistant staphylococcal isolates far exceeded 
that of other ophthalmic fluoroquinolones. Results of sus-
ceptibility retests indicated that besifloxacin was 4–128-
fold more potent against ciprofloxacin-resistant MRSA 
and MRSE compared with other fluoroquinolones. Thus, 
although the methicillin-resistance phenotype does not affect 
fluoroquinolone relative potency, ciprofloxacin resistance, 
which is often concurrent with methicillin resistance, did. 
Silverstein et al recently reported that the in vitro potency 
of besifloxacin was similar to that of vancomycin against 
staphylococcal isolates, including ciprofloxacin-resistant 
MRSA.36 Vancomycin is often used in the treatment of ocular 
MRSA infections.28,37,38
While the superior in vitro activity of besifloxacin against 
drug-resistant staphylococcal isolates is notable, the clinical 
relevance of these in vitro results remains to be shown. Topi-
cal administration of ocular antibiotics results in tear and 
conjunctival tissue concentrations often several-fold higher 
than the MIC, even if the latter is elevated due to development 
of resistance, raising the possibility that some antibacterials 
may be clinically effective even against bacterial strains with 
increased MICs. Nevertheless, the vitro potency of besifloxa-
cin in conjunction with the favorable pharmacokinetic profile 
at the ocular surface39,40 could provide a clinical advantage. 
After a single dose, besifloxacin exposure on the ocular 
surface results in Cmax/MIC and AUC0–24/MIC ratios that are 
well above the generally accepted pharmacodynamic ratios 
required for fluoroquinolone efficacy (ie, Cmax/MIC $ 10 
and AUC0–24/MIC $ 30–50 for Gram-positive bacteria or 
$100–125 for Gram-negative bacteria)41–43 even for drug-
resistant staphylococcal isolates.
In summary, while the spectrum of causative pathogens 
associated with bacterial conjunctivitis has not changed, the 
incidence of resistance of these organisms to antibacterial 
agents has been increasing.23,28,31,32 Thus, there is a need 
for the development of novel anti-infective agents with 
improved potency and activity against drug-resistant 
pathogens. In this integrated data analysis, besifloxacin, a 
novel chlorofluoroquinolone, demonstrated broad-spectrum 
in vitro activity against the causative agents of bacterial 
conjunctivitis, with potent activity against multidrug-resistant 
staphylococcal isolates.
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